KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) EBITDA Margin (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBITDA Margin for 6 consecutive years, with 4389600.0% as the latest value for Q3 2023.

  • On a quarterly basis, EBITDA Margin rose 438969001.0% to 4389600.0% in Q3 2023 year-over-year; TTM through Sep 2023 was 114.24%, a 622.0% decrease, with the full-year FY2024 number at 718937.93%, down 335168207.0% from a year prior.
  • EBITDA Margin was 4389600.0% for Q3 2023 at Twist Bioscience, up from 91.22% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 4389600.0% in Q3 2023 to a low of 324.1% in Q4 2019.
  • A 5-year average of 230902.44% and a median of 113.65% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -12656bps in 2019, then soared 438969001bps in 2023.
  • Twist Bioscience's EBITDA Margin stood at 324.1% in 2019, then skyrocketed by 64bps to 116.63% in 2020, then grew by 7bps to 108.0% in 2021, then grew by 27bps to 79.38% in 2022, then soared by 5529968bps to 4389600.0% in 2023.
  • Per Business Quant, the three most recent readings for TWST's EBITDA Margin are 4389600.0% (Q3 2023), 91.22% (Q2 2023), and 97.1% (Q1 2023).